Pennino Corporation TECHNOLOGY TO IMPROVE LIFE

Transcription

1 Pennino Corporation TECHNOLOGY TO IMPROVE LIFE

2 Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety Foreign Governmental Approval Exit / Liquidity Strategies 2

3 The Opportunity A partnership between Pennino Corp. and New York University (NYU) is developing a drug that decreases body fat, increases lean body mass and lowers cholesterol simultaneously Obesity and related diseases like Type 2 Diabetes, Heart Disease, Stroke and Cancer may be prevented or treated with this technology saving millions of lives and billions in healthcare costs Test data indicates fat weight-loss is 5 times greater and 5 times faster than any drug available or in trials today The discovery may be the secret to how the body converts energy from fat to muscle May open a new area of science and could be a Nobel Prize winning breakthrough 3

4 Highlights of Technology and Company Reduces Obesity/Body Fat - Obesity (Adult and Childhood) is the world s number one health epidemic and is directly tied to Cancer, Diabetes, Heart Disease and Stroke Reduces Type 2 Diabetes - Diabetes is directly correlated to obesity and is a leading health expenditure and the #6 cause of death Reduces Cholesterol Our technology has shown to reduce cholesterol better than any existing drug. Cholesterol is a leading heart disease indicator and cholesterol drugs sell over $30Billion annually Increases Lean Body Mass In addition to reducing body fat we are simultaneously increasing lean body mass - a medical miracle World Class University Partner By partnering with NYU, we are working with the top scientists in the world and with cutting-edge equipment IPO/Acquisition Opportunity A drug that can treat ANY of the above diseases is worth billions. We may treat ALL of them and become the biggest drug in history 4

5 Corporate Profile Incorporated in Delaware Filing in February 2007 Company based in New York, NY Joe Pennino is CEO and Chairman The only asset in the Company is the license from NYU (New York University) 5

6 Joe Pennino CEO and Founder Joe Pennino is an experienced CEO and Wall Street veteran who started his career as a CPA with PriceWaterhouseCoopers. He then worked in the institutional capital markets and investment banking at HSBC, Royal Bank of Scotland and Standard Bank and was based out of New York and London. Mr. Pennino is also an investor in technology companies and has been an executive with many early stage technology companies. Mr. Pennino believes the power of science is critical for the health of the global economy and to improve life. Mr. Pennino holds a Masters in Business Administration from Columbia University and has completed coursework at Columbia University Law School. He holds a degree in Accounting and Finance from University of Illinois and has also completed Executive Education at MIT. 6

7 NYU Relationship Pennino Corp. has exclusive, worldwide license for compound(s) discovered at NYU for various disease indications including Obesity, Type 2 Diabetes, and Cholesterol NYU will receive payments for research and royalties on future sales for the life of patents related to this discovery NYU Scientific Team has two senior PhD's planning and directing all testing to obtain the active molecule(s) NYU also has a dedicated technical staff to execute lab work All work is carried out at NYU facilities under strict security and regulatory guidelines 7

8 Obesity in America

9 Obesity Facts The US is currently spending $150 billion (10% of all medical spending) annually on Obesity and related complications, double the cost in 1998, and more than every Cancer put together By 2018, 40% of Americans will be Obese and spending will rise to $344 billion annually By 2030, 86% of Americans will be Overweight and 51% will be Obese Healthcare costs related to Obesity are expect to double each decade and reach $957 billion annually by 2030, or 1 out of every 6 healthcare dollars spent in the US Obesity is attributed to causing the following percentage of cancers: 49% of endometrial, 35% of esophageal, 28% of pancreatic, 24% of kidney, 21% of gallbladder,17% of breast, and 9% of Colon cancer Worldwide, 1.5 billion people will be overweight or obese by

10 Obesity is a Global Problem 10

11 Global Obesity Map 11

12 Childhood Obesity Facts Michelle Obama has launched a new initiative from the White House against Childhood Obesity working with the Human Health Services Department, the Surgeon General and the FDA 33% of all children are Overweight or Obese today 20% of children ages 6 to 11 are Obese today 18% of children ages 12 to 19 are Obese today 33% of children eventually will suffer diabetes and in Latino and African American communities the number will be 50% 20% of children ages 12 to 19 have High Cholesterol 12

13 Global Childhood Obesity is Exploding 13

14 Diabetes Facts The number of Americans with Diabetes is expected to double in the next 25 years from the current 23.7 million to 44.1 million by 2034 Aging Baby Boomers will have a huge effect on Diabetes and Medicare- currently 8.2million with Diabetes are covered by Medicare costing $45 billion annually and by million with Diabetes will be covered by Medicare costing $171 billion annually 57 million Americans are pre-diabetic today 1.6 million new cases of Diabetes are diagnosed each year Diabetes is associated with Heart Disease, Stroke, High Blood Pressure, Blindness, Nervous System Disease, Kidney Disease, and often requires lower limb amputation 14

15 Diabetes in the US 15

16 Global Diabetes Map

17 Correlation of Adult Obesity & Diabetes 17

18 Next Stage of Development Money raised today will complete the isolation of the active molecule(s) NYU has experts in isolating and identifying key molecules from plants Discovery of the molecule is a mathematical process-of-elimination: Assuming there are 500 chemicals in the extract, the scientists will quickly identify and eliminate the vast majority of known chemicals and focus on the remainder until we find the key compound(s) A combination of high tech/expensive equipment, cell culture, and animal studies are being used Once molecule(s) is/are identified, patents will be filed to protect our very valuable intellectual property NYU will likely publish the discovery in medical journals where it should become a global headline story 18

19 Efficacy and Safety The results achieved so far are: significantly greater than those from competitors beyond FDA minimum requirements (5% reduction in body fat) Our test demonstrated close to a 25% reduction in body fat, or 5x greater than necessary Doctors have stated they need to see a 10-15% fat reduction to be considered a useful drug The plant is organic and has been eaten by humans before without negative side effects giving us comfort that this drug is safe. Our own NYU PhD. ate the plant extract himself with: no noticeable negative side effects positive effects of fat reduction, lean body maintenance and lowered cholesterol 19

20 Foreign Government Drug Approval Obesity, Type 2 Diabetes, Cancer, Heart Disease, high Cholesterol, etc are global health problems and Pennino Corp. will seek approval for drug sales in many countries The FDA is often considered the most difficult agency and other agencies move faster with fewer restrictions It is therefore likely that we will be able to sell the drug internationally before we can sell the drug in the US Pennino Corp. will hire the appropriate consultants and work with foreign agencies to meet the requirements to sell our drug in their respective countries Pennino Corp. sees revenue opportunities globally since most people in the world suffer from the diseases we hope to solve 20

21 Exit / Liquidity Strategies IPO There are 2 possible exit strategies: IPO or Acquisition An IPO is most likely to occur around Phase 2 when the valuation has increased within the investing community Proceeds from IPO s are used to continue clinical trials and offers liquidity to investors An IPO for a technology like ours is certain to gather a tremendous amount of interest given the sheer size of the healthcare problems we are addressing Currently we are reviewing the idea of IPO s in New York, London, Dubai and Shanghai 21

22 Exit / Liquidity Strategies - Acquisition An acquisition is the more common route for a bio company and it can happen at any time We would not be surprised to have significant offers even after the patents are filed because Big Pharma is desperate for Patent Pipeline as their important patents are expiring. There is no shortage of both big companies and smaller companies being acquired in recent days: Pfizer acquired Wyeth for $61billion Merck acquired Schering-Plough for $41billion Even smaller, developmental companies get acquired at huge valuations: Cougar Biotechnology was bought by Johnson & Johnson for $1 billion Sirtris was acquired by GlaxoSmithKline for $720 million (FYI, neither of the developmental companies had products approved by the FDA and had drugs for much smaller markets than our target markets. 22

23 Thank You Thank you for reviewing this introductory presentation For more details on the history, data, and future plans, please request our Confidentiality Agreement and we will schedule a meeting with you. We look forward to working with you Joe Pennino CEO and Founder Pennino Corporation joe@penninocorp.com 23